Qiagen secures EUA for COVID-19 test

By LabPulse.com staff writers

March 29, 2021 -- Qiagen has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for NeuMoDx, a test that helps clinicians distinguish types of respiratory disease.

NeuMoDx Flu A-B/ respiratory syncytial virus (RSV)/SARS-CoV-2 Vantage is a polymerase chain reaction (PCR) assay that will enable clinicians to identify the cause of respiratory viral infection, whether it's due to SARS-CoV-2, influenza, or RSV.

The test has been in use in the European Union since last November, Qiagen said.


Copyright © 2021 LabPulse.com
 

To read this and get access to all of the exclusive content on LabPulse.com, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a LabPulse.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?